Sec Form 3 Filing - Lu Peng @ Pharvaris N.V. - 2026-03-18

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Lu Peng 2. Issuer Name and Ticker or Trading Symbol Pharvaris N.V. [ PHVS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Medical Officer (Last) (First) (Middle) 1 CRANBERRY HILL SUITE 400 3. Date of Earliest Transaction (MM/DD/YY) 03/18/2026 (Street) LEXINGTON, MA02421 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 66,309 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 28 ( 2 ) 03/03/2036 Common Stock 70,000 D Stock Option (Right to Buy) $ 16.05 ( 3 ) 03/12/2035 Common Stock 67,500 D Stock Option (Right to Buy) $ 22.31 ( 4 ) 04/11/2034 Common Stock 65,000 D Stock Option (Right to Buy) $ 8.05 ( 5 ) 04/06/2033 Common Stock 73,118 D Stock Option (Right to Buy) $ 8.05 ( 6 ) 04/06/2033 Common Stock 6,882 D Stock Option (Right to Buy) $ 18.14 ( 7 ) 04/01/2032 Common Stock 57,669 D Stock Option (Right to Buy) $ 18.14 ( 8 ) 04/01/2032 Common Stock 7,301 D Stock Option (Right to Buy) $ 20 ( 9 ) 02/05/2031 Common Stock 14,000 D Stock Option (Right to Buy) $ 20 ( 9 ) 02/05/2031 Common Stock 65,000 D Stock Option (Right to Buy) $ 2.59 ( 10 ) 02/03/2030 Common Stock 245,308 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Lu Peng 1 CRANBERRY HILL SUITE 400 LEXINGTON, MA02421 Chief Medical Officer Signatures /s/ Marnus Nel, Attorney-in-Fact for Peng Lu 03/18/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: - 25,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -17,250 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -11,120 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter. ( 2 )25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter. ( 3 )25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter. ( 4 )25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter. ( 5 )25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. ( 6 )25% of the option vested on January 6, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter. ( 7 )25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. ( 8 )25% of the option vested on January 1, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter. ( 9 )25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter. ( 10 )25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.